Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma …
Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions , authorizing marketing of ADCETRIS for two lymphoma indications: the treatment of patients with Hodgkin lymphoma after failure of autologous st…